Shares of DaVita have moved -4.5% today, and are now trading at a price of $77.92. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 984,953 compared to the stock's average volume of 999,734.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. Based in Denver, United States the company has 70,000 full time employees and a market cap of $7,114,095,616.
The company is now trading -31.04% away from its average analyst target price of $113.0 per share. The 6 analysts following the stock have set target prices ranging from $100.0 to $142.0, and on average give DaVita a rating of hold.
Over the last 12 months DVA shares have declined by -13.0%, which represents a difference of -27.0% when compared to the S&P 500. The stock's 52 week high is $116.97 per share and its 52 week low is $65.28. With its net margins declining an average -3.6% over the last 6 years, DaVita declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-22 | 11,609,894 | 560,400 | 5 | -37.5 |
| 2022-02-11 | 11,618,797 | 978,450 | 8 | 14.29 |
| 2021-02-12 | 11,550,604 | 773,642 | 7 | 0.0 |
| 2020-02-21 | 11,388,479 | 810,981 | 7 | 600.0 |
| 2019-02-22 | 11,404,851 | 159,394 | 1 | -83.33 |
| 2018-02-23 | 10,876,634 | 663,618 | 6 |
